Clinical Trial Update: Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind trial evaluating cenobamate as adjunctive therapy for primary generalized epilepsy (PGTC seizures) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Epilepsy

Drugs mentioned

• Xcopri (cenobamate) (cenobamate)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Primary Generalized Epilepsy | Phase 3 | Status: COMPLETED